SCHEMBL10270827

SCHEMBL10270827

Cc1ccccc1C(CNS(C)(=O)=O)NC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.44
▸ HPGD P15428 5/20 0.44
▸ HTT P42858 5/20 0.44
▸ NPSR1 Q6W5P4 5/20 0.44
▸ PKM P14618 4/20 0.44
▸ XBP1 P17861 3/20 0.44
▸ JAK2 O60674 3/20 0.44
▸ HSD17B10 Q99714 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ S1PR4 O95977 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ ALOX15 P16050 2/20 0.44
▸ TP53 P04637 2/20 0.44
▸ S1PR1 P21453 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ ALDH1A1 P00352 5/20 0.43
▸ HSP90AA1 P07900 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12522768 0.89 LMNA (0.43) LMNAHPGDHTTNPSR1PKM
SCHEMBL10217111 0.87 CA12 (0.41) LMNAHPGDHTTNPSR1PKM
SCHEMBL10216773 0.85 AVPR2 (0.46) LMNAHPGDHTTNPSR1PKM
SCHEMBL10270248 0.84 AVPR2 (0.40) LMNAHPGDHTTNPSR1PKM
SCHEMBL10216786 0.82 AVPR2 (0.46) LMNAHPGDHTTNPSR1PKM
SCHEMBL10270101 0.82 JAK2 (0.43) LMNAHPGDHTTNPSR1PKM
SCHEMBL22457063 0.82 JAK2 (0.43) LMNAHPGDHTTNPSR1PKM
SCHEMBL29748599 0.82 JAK2 (0.43) LMNAHPGDHTTNPSR1PKM
SCHEMBL29747547 0.82 JAK2 (0.43) LMNAHPGDHTTNPSR1PKM
SCHEMBL31757758 0.80 CTSA (0.55) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238607-A1 SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-09-20 — — US disclosed
US-8202895-B2 Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-06-19 — — US disclosed
US-20100261771-A1 SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238607-A1 SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF AADAC, NAT1, TNNT2 LMNA 726/4885HPGD 782/4885HTT 2154/4885
US-20100261771-A1 SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF AADAC, NAT1, TNNT2 LMNA 726/4885HPGD 782/4885HTT 2154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback